News
Sarepta shares slump after report of patient death in early-stage study
Shares of Sarepta Therapeutics declined 16.5% to $18.32 in premarket trading on Friday after a Bloomberg report that a patient enrolled in an early-stage study of one of the company's gene therapies has died from acute liver failure.
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
GlobalData on MSN22h
Sarepta Therapeutics to cut 500 jobs amid restructuringThe company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.
The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, ...
Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...
The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.
Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...
Sarepta stock surged after the pharma company said it would lay off a third of its workforce and add a black-box warning to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback